NCT07330206

Brief Summary

Study type: Multicenter retrospective cohort study with prospective validation Primary purpose: To determine whether an individualized, imaging-guided treatment algorithm Ventriculoperitoneal shunt (VPS) vs endoscopic third ventriculostomy (ETV) improves 2-year neurodevelopmental outcomes in children \<18 y with congenital hydrocephalus. Main questions

  • Does ETV produce higher 6-month surgical success and lower 2-year re-intervention rates than VPS in prespecified subgroups (age ≥3 y, obstructive hydrocephalus, normal basal cisterns)?
  • Does a machine-learning model (ETV-PS) using pre-operative MRI features accurately predict ETV success (AUC ≥0.80) and thereby reduce unnecessary re-operations?
  • Does early, frequent programmable-valve pressure adjustment after VPS decrease over-shunting headaches and improve 2-year cognitive scores compared with standard, infrequent adjustment? Comparison: ETV group vs. VPS group (1:1 propensity-matched); within VPS cohort, frequent (≥3 adjustments in first 6 mo) vs. infrequent (\<3) pressure-tuning arms. Participants will
  • Provide pre-operative clinical data and MRI/CT imaging.
  • Undergo either VPS or ETV as clinically indicated; 320 VPS recipients receive programmable valves with protocol-driven pressure logs.
  • Return for standardized neurodevelopmental testing Children's Memory Scale (CMS), Wechsler Intelligence Scale for Children(WISC), Pediatric Quality of Life Inventory(PedsQL) and imaging at 6 mo, 1 y and 2 y; valve adjustments tracked electronically.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
800

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jan 2016

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2016

Completed
8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 30, 2023

Completed
21 days until next milestone

Study Completion

Last participant's last visit for all outcomes

January 20, 2024

Completed
1.9 years until next milestone

First Submitted

Initial submission to the registry

December 29, 2025

Completed
11 days until next milestone

First Posted

Study publicly available on registry

January 9, 2026

Completed
Last Updated

January 12, 2026

Status Verified

May 1, 2024

Enrollment Period

8 years

First QC Date

December 29, 2025

Last Update Submit

January 8, 2026

Conditions

Keywords

Ventriculoperitoneal ShuntEndoscopic Third VentriculostomyMachine LearningIndividualized TreatmentLong-term Prognosis

Outcome Measures

Primary Outcomes (1)

  • Surgical success rate at 6 months post-operation

    defined as stable or reduced ventricular volume on MRI/CT without need for re-intervention.

    6 months

Secondary Outcomes (2)

  • 2-year re-intervention rate

    2 years

  • Cognitive improvement

    2 years

Study Arms (2)

ETV group

All undergo endoscopic third ventriculostomy as initial treatment

Diagnostic Test: MRI-Guided Precision Shunt or ETV Strategy

VPS group

* 320 receive a programmable valve with protocol-driven pressure adjustments * 80 receive a fixed-pressure valve (included only in VPS-vs-ETV comparisons, excluded from valve-management sub-analysis)

Diagnostic Test: MRI-Guided Precision Shunt or ETV Strategy

Interventions

ETV groupVPS group

Eligibility Criteria

AgeUp to 17 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)
Sampling MethodNon-Probability Sample
Study Population

800 children ≤17 years with congenital hydrocephalus recruited from 6 tertiary pediatric neurosurgical centers; 1:1 matched VPS (n=400) vs ETV (n=400) cohorts balanced for age, sex, and hydrocephalus subtype.

You may qualify if:

  • Age 0-17.99 years at surgery
  • Congenital hydrocephalus confirmed by clinical and MRI/CT findings
  • First surgical treatment: either VPS or ETV
  • Complete pre-operative MRI/CT and ≥ 2-year follow-up data available

You may not qualify if:

  • Secondary hydrocephalus (tumor, infection, trauma)
  • Severe comorbidities affecting neuro-developmental assessment (e.g., major congenital heart disease, genetic-metabolic disorders)
  • Incomplete baseline imaging or follow-up \< 2 years

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

West China Hospital of Sichuan University

Chengdu, Sichuan, China

Location

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

December 29, 2025

First Posted

January 9, 2026

Study Start

January 1, 2016

Primary Completion

December 30, 2023

Study Completion

January 20, 2024

Last Updated

January 12, 2026

Record last verified: 2024-05

Data Sharing

IPD Sharing
Will share
Shared Documents
STUDY PROTOCOL

Locations